Given the conflicting data on the safety and efficacy of everolimus in halting the progression of glomerulonephritis and the promising role of BMDSCs in the repair of injured tissues with minimal adverse effects, the current study was designed to compare the protective effect of everolimus vs. BMDSCs on anti-Thy1-induced glomerulonephritis in rats. This evidence concerns the gene THY1 and glomerulonephritis.